Statin–Ezetimibe Combination Therapy versus Statin Monotherapy in Atherosclerotic Cardiovascular Disease: A Prespecified Secondary Analysis of the Randomized Ez-PAVE Trial
Primary result · Composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, any revascularization, or hospitalization for unstable anginaResult — go to the resultHazard ratio 1.07 95% CI 0.83–1.37Authors' conclusion
Within a target-directed LDL-C-lowering strategy, cardiovascular efficacy and safety did not differ significantly, whether initiated as statin-ezetimibe combination therapy or as statin monotherapy, but combination therapy facilitated achievement of a lower LDL-C target.
Study context
- Population
- Patients with atherosclerotic cardiovascular disease, enrolled between January 2021 and July 2022, first randomized to an intensive (<55 mg/dL) or conventional (<70 mg/dL) low-density lipoprotein cholesterol (LDL-C)-targeting strategy
- Participants
- 3,048 patients
- Comparison
- Initial statin-ezetimibe combination therapy versus statin monotherapy
- Statin-ezetimibe combination therapyn = 1,525
- Statin monotherapyn = 1,523reference
- Primary endpoint
- Composite of:
- Death from cardiovascular causes
- Nonfatal myocardial infarction
- Nonfatal stroke
- Any revascularization
- Hospitalization for unstable angina
- Follow-up
- 3 years
Methodological details17 centers in South Korea
- 17 centers in South Korea
Primary result
As reported in the abstract
Composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, any revascularization…
Statin-ezetimibe combination therapyvs Statin monotherapy
HR 1.07 (95% CI 0.83–1.37); P = 0.596
Further findings
Median LDL-C during follow-up, intensive-targeting strategy
Median LDL-C during follow-up, conventional-targeting strategy
Ezetimibe added during follow-up among patients initially on statin monotherapy
Patients
- Intensive-targeting strategy, of those initially on statin monotherapy
- 241 (34.3%)
- Conventional-targeting strategy, of those initially on statin monotherapy
- 177 (24.8%)
Treatment effect of intensive- vs conventional-targeting strategies by therapy regimen
- Consistent regardless of therapy regimens without significant heterogeneity
- P interaction =0.583
Original publication
Statin–Ezetimibe Combination Therapy versus Statin Monotherapy in Atherosclerotic Cardiovascular Disease: A Prespecified Secondary Analysis of the Randomized Ez-PAVE Trial. Circulation. Published 7 November 2026. doi:10. 1161/ circulationaha. 126. 083811
Composed by AI from the published abstract and checked against it. How Briefs are made →